Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.70 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8554508 | 1.00 | HRH3 (0.70) | HRH3KEAP1SMN1; SMN2MAPTSIGMAR1 | |
| SCHEMBL854695 | 1.00 | HRH3 (0.70) | HRH3KEAP1SMN1; SMN2MAPTSIGMAR1 | |
| SCHEMBL11179088 | 1.00 | HRH3 (0.70) | HRH3KEAP1SMN1; SMN2MAPTSIGMAR1 | |
| SCHEMBL21799504 | 0.97 | HRH3 (0.75) | HRH3KEAP1SMN1; SMN2MAPTSIGMAR1 | |
| Hydrazine SCHEMBL8556857 | 0.97 | HRH3 (0.67) | HRH3KEAP1SMN1; SMN2MAPTSIGMAR1 | |
| SCHEMBL7230416 | 0.97 | HRH3 (0.75) | HRH3KEAP1SMN1; SMN2MAPTSIGMAR1 | |
| SCHEMBL491616 | 0.97 | HRH3 (0.75) | HRH3KEAP1SMN1; SMN2MAPTSIGMAR1 | |
| SCHEMBL21799578 | 0.97 | HRH3 (0.75) | HRH3KEAP1SMN1; SMN2MAPTSIGMAR1 | |
| SCHEMBL21799790 | 0.97 | HRH3 (0.75) | HRH3KEAP1SMN1; SMN2MAPTSIGMAR1 | |
| SCHEMBL5839696 | 0.97 | HRH3 (0.75) | HRH3KEAP1SMN1; SMN2MAPTSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103122364-A | Antitubercular inhibitor screened target gene Rv2498c and application thereof | UNIV HUAZHONG AGRICULTURAL | 2013-05-29 | — | — | CN | claimed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023071601-A1 | DESLORATADINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 天津市昕晨投资发展有限公司 | 2023-05-04 | — | — | WO | disclosed |
| US-6878736-B1 | Histamine H3 receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2005-04-12 | — | — | US | disclosed |
| EP-1056733-B1 | HISTAMINE H3 RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2004-01-07 | — | — | EP | disclosed |
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | AVENTIS PHARMACEUTICALS INC. | 2003-08-14 | — | — | US | disclosed |
| US-6541505-B1 | Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. | AVENTIS PHARMACEUTICALS INC. | 2003-04-01 | — | — | US | disclosed |
| EP-1140901-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| CN-1031618-C | Immunomodulatory azaspiranes | SMITHKLINE BECKMAN CORP (US) | 1996-04-24 | — | — | CN | disclosed |
| EP-0310321-B1 | Immunomodulatory azaspiranes | SMITHKLINE BEECHAM CORP (US) | 1994-11-30 | — | — | EP | disclosed |
| WO-1989002889-A1 | IMMUNOMODULATORY AZASPIRANES | SMITHKLINE BECKMAN CORPORATION (US) | 1989-04-06 | — | — | WO | disclosed |
| EP-0310321-A2 | Immunomodulatory azaspiranes | SMITHKLINE BEECHAM CORPORATION (US) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | HRH3 2171/4885KEAP1 4175/4885SMN1; SMN2 2768/4885 |
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | SERPINC1, F2, F11 | HRH3 908/4885KEAP1 1243/4885SMN1; SMN2 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.